Research Analysts Set Expectations for STERIS Q3 Earnings

STERIS plc (NYSE:STE - Free Report) - Investment analysts at Zacks Research cut their Q3 2025 earnings per share estimates for shares of STERIS in a research note issued on Thursday, October 24th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.20 per share for the quarter, down from their prior estimate of $2.27. The consensus estimate for STERIS's current full-year earnings is $9.06 per share. Zacks Research also issued estimates for STERIS's Q1 2026 earnings at $2.03 EPS, Q3 2026 earnings at $2.30 EPS and Q1 2027 earnings at $2.23 EPS.

A number of other equities analysts have also recently weighed in on the company. JMP Securities restated a "market outperform" rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research report on Thursday, August 8th. Stephens reissued an "overweight" rating and set a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Monday, October 21st. Finally, KeyCorp raised their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $253.00.

STERIS Stock Down 0.0 %

NYSE STE traded down $0.11 on Monday, reaching $224.01. The company had a trading volume of 491,131 shares, compared to its average volume of 474,217. The firm has a market capitalization of $22.09 billion, a PE ratio of 55.91 and a beta of 0.84. STERIS has a 1 year low of $195.47 and a 1 year high of $248.24. The firm has a 50-day moving average of $234.76 and a 200-day moving average of $226.46. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion during the quarter, compared to analysts' expectations of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. STERIS's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.00 EPS.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were issued a dividend of $0.57 per share. This is a positive change from STERIS's previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend was Thursday, September 5th. STERIS's payout ratio is presently 56.58%.

Insider Buying and Selling

In related news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other STERIS news, Director Christopher S. Holland sold 473 shares of the firm's stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares of the company's stock, valued at $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On STERIS

Institutional investors have recently bought and sold shares of the business. Central Pacific Bank Trust Division acquired a new stake in shares of STERIS during the 3rd quarter valued at about $28,000. J.Safra Asset Management Corp lifted its holdings in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 53 shares during the last quarter. Quent Capital LLC lifted its holdings in shares of STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 71 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of STERIS during the 1st quarter valued at about $36,000. Finally, Versant Capital Management Inc lifted its holdings in shares of STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider's stock valued at $41,000 after buying an additional 181 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.